Tag: Cancer: Prostate
Care at High-Volume Radiation Treatment Centers Tied to Higher Survival
Findings seen among men with very high-risk prostate cancer
Survival Similar for Black, White Prostate Cancer Patients in Clinical Trial Setting
Median PFS, OS similar for Black and White patients receiving first- or second-generation androgen receptor pathway inhibitors
PSMA-PET Improves Prediction of Biochemical Recurrence in Prostate Cancer
Risk assessment for biochemical recurrence improved with addition of PSMA PET N1/M1 status to presurgical Cancer of the Prostate Risk Assessment score
Toxicity Reduced With MRI-Guided Radiotherapy for Prostate Cancer
Odds ratios for acute grade 2 or higher genitourinary and gastrointestinal toxicities reduced for MRg-A-SBRT versus CT-SBRT
For Prostate Cancer Info Videos, Patients Prefer Hearing From a Physician
And, racial concordance between patient and physician important for trust among Black adults
Indigenous Men Less Likely to Receive PSA Testing
Indigenous men with prostate cancer are also more likely to have higher-risk disease characteristics
American Indian/Alaska Native Men Less Likely to Receive Prostate Screening
Data from NAMCS revealed AI/AN men were less likely to receive PSA test and/or digital rectal examination than non-Hispanic White men
FDA Approves Talzenna for Metastatic, Castration-Resistant Prostate Cancer
Significant radiographic progression-free survival seen for homologous recombination repair gene mutation, including with BRCA mutation
ASCO: Drug Combo Ups Progression-Free Survival for Metastatic Prostate Cancer
Improvement in radiographic progression-free survival seen for talazoparib plus enzalutamide as first-line treatment
Genetically Adjusted PSA Levels Improve Prediction of Prostate Cancer
Genetically adjusted prostate-specific antigen more predictive of aggressive prostate cancer than unadjusted PSA
